Skip to main content
Ann Silk, MD, Oncology, Boston, MA

AnnWillmanSilkMD

Oncology Boston, MA

Cutaneous Oncology

Dr. Silk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Silk's full profile

Already have an account?

  • Office

    Dana-Farber Cancer Institute
    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-6571

Education & Training

  • University of Michigan
    University of MichiganFellowship, Hematology and Medical Oncology, 2011 - 2014
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2008 - 2011
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 2008
  • Swarthmore College
    Swarthmore CollegeBA, Biology, 1997 - 2001
  • Swarthmore College
    Swarthmore CollegeB.S., Biology (concentration in Environmental Studies), 2001
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineM.S., Clinical Research

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2018 - 2025
  • NJ State Medical License
    NJ State Medical License 2014 - 2019
  • MI State Medical License
    MI State Medical License 2011 - 2014
  • PA State Medical License
    PA State Medical License 2008 - 2011

Awards, Honors, & Recognition

  • Project Member Team Award (PMTA) National Institutes of Health (NIH) Cancer Therapeutics and Evaluation, 2015
  • Excellence in Research Award, Hematology/ Oncology Fellowship Program University of Michigan, 2014
  • Outstanding Clinical Research Paper Award University of Michigan, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors  
    Jeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
  • Clinical characterization of colitis arising from anti-PD-1 based therapy  
    Wang DY, Mooradian MJ, Kim DW, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert ..., OncoImmunol, 1/1/2018
  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma  
    Weber J, Mandala M, Del Vecchio M, and the CheckMate 238 Collaborators (Silk AW), N Engl J Med, 1/1/2017
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
    Stein MN, Malhotra J, Malhotra U, Silk AW, Chan N, Rodriguez-Rodriguez L, Aisner J, Aiken R, Newman J, Sadimin E, Saunders T, Frankel M, Kareddula A, El-Deiry WS, Tara..., J Clin Oncol, 1/1/2018
  • A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carci...
    Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, Moore D, Goydos JS, Chen HX, Kaufman H, Zloza A, Mehnert JM, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
  • A Phase I Study to Evaluate the Safety of Trigriluzole (BHV-4157) in Combination with PD-1 Blocking Antibodies.
    Silk AW, Berman R, Coric V, Ruggiero L, Reitz AB, Shih W, Kane MP, Mehnert JM, Pelletier JC, Zloza A, Goydos JS, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
  • Join now to see all

Lectures

  • Oncolytic Viral Therapy in Melanoma and Merkel Cell Carcinoma: What�s Good for the Goose is Good for the Gander 
    University of Pittsburgh Medical Center, Pittsburgh, PA - 1/1/2018
  • Oncolytic Viral Therapy 
    Rutgers Robert Wood Johnson Medical School - 1/1/2018
  • Practical Radiology for Fellows 
    Rutgers Robert Wood Johnson Medical School - 1/1/2018
  • Join now to see all

Press Mentions

  • What Is Basal Cell Carcinoma, the Skin Cancer Biden Just Had
    What Is Basal Cell Carcinoma, the Skin Cancer Biden Just HadMarch 3rd, 2023
  • Society for Immunotherapy of Cancer (SITC) Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Nonmelanoma Skin Cancer
    Society for Immunotherapy of Cancer (SITC) Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Nonmelanoma Skin CancerAugust 3rd, 2022
  • New Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers
    New Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin CancersMay 24th, 2021
  • Join now to see all

Grant Support

  • Combination oncolytic virus and PD-1 blockade for melanoma treatmentGateway for Cancer Research2016–2018

Professional Memberships